Edmund Omoruyi
Overview
Explore the profile of Edmund Omoruyi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Heesbeen R, Bastian A, Omoruyi E, Rosen J, Comeaux C, Callendret B, et al.
Vaccine
. 2024 Sep;
42(26):126273.
PMID: 39276619
Background: Respiratory syncytial virus (RSV) can cause severe illness in older adults. A combination vaccine containing Ad26.RSV.preF and purified recombinant RSV preF protein has previously demonstrated efficacy and tolerability in...
2.
Langley J, Nolan T, Ramet M, Richmond P, Rosario Filho N, Haazen W, et al.
Open Forum Infect Dis
. 2024 Sep;
11(9):ofae453.
PMID: 39220658
Background: Respiratory syncytial virus (RSV) causes serious illness in children. The Ad26.RSV.preF vaccine candidate was immunogenic with acceptable safety in a phase 1/2a study of RSV-seropositive children. Here, we assessed...
3.
Comeaux C, Bart S, Bastian A, Klyashtornyy V, De Paepe E, Omoruyi E, et al.
J Infect Dis
. 2023 Jul;
229(1):19-29.
PMID: 37433021
Background: Ad26.RSV.preF is an adenovirus serotype 26 vector-based respiratory syncytial virus (RSV) vaccine encoding a prefusion conformation-stabilized RSV fusion protein (preF) that demonstrated robust humoral and cellular immunogenicity and showed...
4.
Stuart A, Virta M, Williams K, Seppa I, Hartvickson R, Greenland M, et al.
J Infect Dis
. 2022 Oct;
227(1):71-82.
PMID: 36259542
Background: Respiratory syncytial virus (RSV) remains a leading cause of pediatric morbidity, with no approved vaccine. We assessed the safety and immunogenicity of the Ad26.RSV.preF vaccine candidate in adults and...
5.
Sadoff J, De Paepe E, Haazen W, Omoruyi E, Bastian A, Comeaux C, et al.
J Infect Dis
. 2020 Aug;
223(4):699-708.
PMID: 32851411
Background: Respiratory syncytial virus (RSV) and influenza cause significant disease burden in older adults. Overlapping RSV and influenza seasonality presents the opportunity to coadminister vaccines for both infections. This study...
6.
Williams K, Bastian A, Feldman R, Omoruyi E, De Paepe E, Hendriks J, et al.
J Infect Dis
. 2020 Apr;
222(6):979-988.
PMID: 32320465
Background: Despite the high disease burden of respiratory syncytial virus (RSV) in older adults, there is no approved vaccine. We evaluated the experimental RSV vaccine, Ad26.RSV.preF, a replication-incompetent adenovirus 26...
7.
Hezode C, Almasio P, Bourgeois S, Buggisch P, Brown A, Diago M, et al.
Liver Int
. 2017 Jan;
37(9):1304-1313.
PMID: 28135777
Background & Aims: We investigated the efficacy and safety of simeprevir plus daclatasvir in treatment-naïve patients with chronic, genotype 1b hepatitis C virus infection and advanced liver disease, excluding patients...